

# An overview of HER2

Seminars in Oncology

28, 3-11

DOI: [10.1053/sonc.2001.29713](https://doi.org/10.1053/sonc.2001.29713)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Triple-negative breast cancer types exhibit a distinct poor clinical characteristic in lymph node-negative Chinese patients. <i>Oncology Reports</i> , 1994, 20, 987.	1.2	6
2	Systemic treatment and new developments in advanced prostate cancer. <i>European Journal of Cancer</i> , 2001, 37, 147-157.	1.3	15
3	Immunohistochemical Identification of HER-2/ neu Overexpression and CD117 (c-kit) Expression in Multiple Myeloma. <i>Leukemia and Lymphoma</i> , 2002, 43, 2427-2430.	0.6	10
4	Fulminant tumour lysis syndrome in acute myelogenous leukaemia with inv(16)(p13;q22). <i>European Journal of Haematology</i> , 2002, 69, 193-199.	1.1	15
5	Clinical and Molecular Features of Small cell Lung Cancer. <i>Cancer Biology and Therapy</i> , 2002, 1, 105-112.	1.5	7
6	Cyclooxygenase-2 and ERBB-2 in Cholangiocarcinoma: Potential Therapeutic Targets. <i>Seminars in Liver Disease</i> , 2002, 22, 303-314.	1.8	78
7	Trends and Developments in the Pharmacological Treatment of Psoriasis. <i>Acta Dermato-Venereologica</i> , 2002, 82, 401-410.	0.6	10
8	Role of biomarkers for early detection of lung cancer and chemoprevention. <i>European Respiratory Journal</i> , 2002, 19, 1151-1158.	3.1	55
10	CD117 (KIT Receptor) Expression in Merkel Cell Carcinoma. <i>American Journal of Dermatopathology</i> , 2002, 24, 289-293.	0.3	119
11	TTF-1 Expression in Pulmonary Adenocarcinomas. <i>American Journal of Surgical Pathology</i> , 2002, 26, 767-773.	2.1	352
12	Antimetastatic Drugs in Prostate Cancer. <i>Clinical Prostate Cancer</i> , 2002, 1, 14-19.	2.1	7
13	Pharmacogenetics, Pharmacogenomics, and Cardiovascular Therapeutics. <i>American Journal of Cardiovascular Drugs</i> , 2002, 2, 287-296.	1.0	12
14	Genetic heterogeneity of single disseminated tumour cells in minimal residual cancer. <i>Lancet, The</i> , 2002, 360, 683-689.	6.3	436
15	Analysis of c-kit protein expression in small-cell lung carcinoma and its implication for prognosis. <i>Human Pathology</i> , 2002, 33, 1182-1187.	1.1	88
16	The diagnostic use of cytogenetic and molecular genetic techniques in the assessment of small round cell tumours. <i>Current Diagnostic Pathology</i> , 2002, 8, 338-348.	0.4	8
17	Overview of tumor lysis syndrome. <i>Seminars in Oncology Nursing</i> , 2002, 18, 2-5.	0.7	9
18	Pathophysiology, signs, and symptoms of acute tumor lysis syndrome. <i>Seminars in Oncology Nursing</i> , 2002, 18, 6-11.	0.7	5
19	Clinical Q & A. <i>Clinical Journal of Oncology Nursing</i> , 2002, 6, 109-110.	0.3	15

#	ARTICLE	IF	CITATIONS
20	Poly(ADP-ribose) polymerase inhibitor increases growth inhibition and reduces G2/M cell accumulation induced by temozolomide in malignant glioma cells. <i>Glia</i> , 2002, 40, 44-54.	2.5	61
21	Adjuvant chemohormonal therapy of high risk prostate carcinoma. <i>Cancer</i> , 2002, 94, 2728-2732.	2.0	15
22	Constitutive activation of met kinase in non-small-cell lung carcinomas correlates with anchorage-independent cell survival. <i>Journal of Cellular Biochemistry</i> , 2002, 86, 665-677.	1.2	25
23	Highlights of contemporary issues in the medical management of prostate cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2002, 43, 105-121.	2.0	17
24	Sti-571 in Chronic Myelogenous Leukaemia. <i>British Journal of Haematology</i> , 2002, 119, 15-24.	1.2	23
25	Clinical Aspects of Gliomas. <i>Medical Laser Application: International Journal for Laser Treatment and Research</i> , 2002, 17, 91-104.	0.4	2
26	Genetic alterations responsible for metastatic phenotypes of lung cancer cells. <i>Clinical and Experimental Metastasis</i> , 2003, 20, 189-193.	1.7	22
28	p53 and Bcl-2 Protein Expression and Its Relationship with Prognosis in Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2003, 4, 298-302.	1.1	20
29	Cell Cycle Modulators for the Treatment of Lung Malignancies. <i>Clinical Lung Cancer</i> , 2003, 5, 158-168.	1.1	24
30	Inhibition of pancreatic stellate cell activation by the hydroxymethylglutaryl coenzyme A reductase inhibitor lovastatin. <i>Biochemical Pharmacology</i> , 2003, 65, 1295-1303.	2.0	36
31	Investigation of anticancer mechanism of thiaziazole-based compound in human non-small cell lung cancer A549 cells. <i>Biochemical Pharmacology</i> , 2003, 66, 115-124.	2.0	114
32	Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer. <i>Cancer</i> , 2003, 98, 1048-1054.	2.0	130
33	BRCA1 gene in breast cancer. <i>Journal of Cellular Physiology</i> , 2003, 196, 19-41.	2.0	228
34	Peracute onset of severe tumor lysis syndrome immediately after 4 Gy fractionated TBI as part of reduced intensity preparative regimen in a patient with T-ALL with high tumor burden. <i>Bone Marrow Transplantation</i> , 2003, 31, 935-937.	1.3	17
35	Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. <i>Leukemia</i> , 2003, 17, 1707-1712.	3.3	101
36	Kit Expression in Small Cell Carcinomas of the Lung: Effects of Chemotherapy. <i>Modern Pathology</i> , 2003, 16, 1041-1047.	2.9	52
37	Implications of growth factor alterations in the treatment of pancreatic cancer. <i>Molecular Cancer</i> , 2003, 2, 5.	7.9	9
38	Imatinib Mesylate. <i>Drugs</i> , 2003, 63, 513-522.	4.9	100

#	ARTICLE	IF	CITATIONS
39	Pharmacogenetics of Anticancer Drug Sensitivity in Non-Small Cell Lung Cancer. <i>Pharmacological Reviews</i> , 2003, 55, 57-103.	7.1	65
40	Dissecting the genetic alterations involved in lung carcinogenesis. <i>Lung Cancer</i> , 2003, 40, 111-121.	0.9	32
41	EGF receptor as a therapeutic target. <i>Lung Cancer</i> , 2003, 41, 9-14.	0.9	60
42	E-90. Molecular pathology of small cell lung cancer. <i>Lung Cancer</i> , 2003, 41, S109.	0.9	0
43	Early versus late hormonal therapy: debating the issues. <i>Urology</i> , 2003, 61, 8-13.	0.5	11
44	A review of clinical and laboratory findings and treatment of tumor lysis syndrome. <i>Clinica Chimica Acta</i> , 2003, 333, 13-18.	0.5	50
45	Molecular targets in cancer therapy. <i>Seminars in Oncology Nursing</i> , 2003, 19, 193-205.	0.7	11
46	Incidence, Medical Resource Utilisation and Costs of Hyperuricemia and Tumour Lysis Syndrome in Patients with Acute Leukaemia and Non-Hodgkin's Lymphoma in Four European Countries. <i>Leukemia and Lymphoma</i> , 2003, 44, 77-83.	0.6	134
48	Lung cancer * 9: Molecular biology of lung cancer: clinical implications. <i>Thorax</i> , 2003, 58, 892-900.	2.7	110
49	Efficacy and Safety of Rasburicase (recombinant urate oxidase) for the Prevention and Treatment of Hyperuricemia During Induction Chemotherapy of Aggressive Non-Hodgkin's Lymphoma: Results of the GRAAL1 (Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma) Study. <i>Journal of Clinical Oncology</i> , 2003, 21, 4402-4406.	0.8	216
50	Her-2/neuGene Amplification in Familial vs Sporadic Breast Cancer. <i>American Journal of Clinical Pathology</i> , 2003, 120, 917-927.	0.4	9
51	Spontaneous Acute Tumor Lysis Syndrome in a DBA/1J Mouse: A Case Report and Review. <i>Toxicologic Pathology</i> , 2003, 31, 486-490.	0.9	11
52	Airway stents provide symptomatic relief. <i>Thorax</i> , 2003, 58, 900-900.	2.7	0
53	Acute Tumor Lysis Syndrome Secondary to Hydroxyurea in Acute Myeloid Leukemia. <i>Annals of Pharmacotherapy</i> , 2003, 37, 675-678.	0.9	13
54	Targeting the type 1 insulin-like growth factor receptor as anti-cancer treatment. <i>Anti-Cancer Drugs</i> , 2003, 14, 669-682.	0.7	64
55	The rationale for adjuvant chemotherapy for high-risk prostate cancer. <i>Current Opinion in Urology</i> , 2003, 13, 123-131.	0.9	2
56	Imatinib mesylate inhibits autonomous erythropoiesis in patients with polycythemia vera in vitro. <i>Blood</i> , 2003, 102, 2240-2242.	0.6	37
57	Inhibition of acute lymphoblastic and myeloid leukemias by a novel kinase inhibitor. <i>Blood</i> , 2003, 102, 4153-4158.	0.6	25

#	ARTICLE	IF	CITATIONS
59	Monoclonal antibodies in the treatment of cancer, part 1. American Journal of Health-System Pharmacy, 2003, 60, 1531-1548.	0.5	34
60	Role of i.v. allopurinol and rasburicase in tumor lysis syndrome. American Journal of Health-System Pharmacy, 2003, 60, 2213-2222.	0.5	25
62	Incidence and Pathogenesis of Tumor Lysis Syndrome. , 2004, 147, 61-68.		49
63	RBSP3 (HYA22) is a tumor suppressor gene implicated in major epithelial malignancies. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 4906-4911.	3.3	88
64	Phase II study of the farnesyl transferase inhibitor R115777 in patients with sensitive relapse small-cell lung cancer. Annals of Oncology, 2004, 15, 1187-1193.	0.6	82
65	Growth Factor Independence-1 Is Expressed in Primary Human Neuroendocrine Lung Carcinomas and Mediates the Differentiation of Murine Pulmonary Neuroendocrine Cells. Cancer Research, 2004, 64, 6874-6882.	0.4	71
66	A Multicenter Phase I Gene Therapy Clinical Trial Involving Intraperitoneal Administration of E1A-Lipid Complex in Patients with Recurrent Epithelial Ovarian Cancer Overexpressing HER-2/neu Oncogene. Clinical Cancer Research, 2004, 10, 2986-2996.	3.2	76
67	Enhanced therapeutic effects of doxorubicin and paclitaxel in combination with liposome-entrapped ends-modified raf antisense oligonucleotide against human prostate, lung and breast tumor models. International Journal of Oncology, 2004, 24, 1181.	1.4	5
68	Global Gene Expression Analysis of Human Bronchial Epithelial Cells Treated with Tobacco Condensates. Cell Cycle, 2004, 3, 1152-1166.	1.3	33
70	Use of Single-Dose Rasburicase in an Obese Female. Annals of Pharmacotherapy, 2004, 38, 1428-1431.	0.9	26
71	Hyperuricemic Syndromes in Cancer Patients. , 2004, 147, 47-60.		20
72	Bayesian Pharmacokinetically Guided Dosing of Paclitaxel in Patients with Non-Small Cell Lung Cancer. Clinical Cancer Research, 2004, 10, 2237-2244.	3.2	47
73	Complete disappearance of multiple periorbital xanthelasmata after chemotherapy for primary extragonadal germ-cell mediastinal tumor. Annals of Oncology, 2004, 15, 1445-1446.	0.6	0
74	Pediatric Tumor Lysis Syndrome. Journal of Pharmacy Practice, 2004, 17, 447-454.	0.5	3
75	Evolution of somatic mutations in mammary tumors in transgenic mice is influenced by the inherited genotype. BMC Medicine, 2004, 2, 24.	2.3	49
76	Abnormalities in chromosome 17 and p53 in lung carcinoma cells detected by fluorescence in situ hybridization. Pathology International, 2004, 54, 413-419.	0.6	9
77	Phase II Trial of Cisplatin Plus Temozolomide, in Recurrent and Progressive Malignant Glioma Patients. Journal of Neuro-Oncology, 2004, 66, 203-208.	1.4	64
78	Molecular pathogenesis of oligodendroglial tumors. Journal of Neuro-Oncology, 2004, 70, 161-181.	1.4	99

#	ARTICLE	IF	CITATIONS
79	Pathology and molecular genetics of astrocytic gliomas. <i>Journal of Molecular Medicine</i> , 2004, 82, 656-670.	1.7	147
80	Novel approaches for the treatment of small cell lung cancer. <i>Hematology/Oncology Clinics of North America</i> , 2004, 18, 499-518.	0.9	7
81	Rasburicase for Prevention of Hyperuricemia and Tumor Lysis Syndrome. <i>Supportive Cancer Therapy</i> , 2004, 1, 77-79.	0.3	0
82	CHK2 kinase expression is down-regulated due to promoter methylation in non-small cell lung cancer. <i>Molecular Cancer</i> , 2004, 3, 14.	7.9	72
83	Recent advances in management of small-cell lung cancer. <i>Cancer Treatment Reviews</i> , 2004, 30, 521-543.	3.4	69
84	Pathophysiology, clinical consequences, and treatment of tumor lysis syndrome. <i>American Journal of Medicine</i> , 2004, 116, 546-554.	0.6	273
85	Tumor Lysis Syndrome. <i>American Journal of Nursing</i> , 2004, 104, 52-53.	0.2	0
86	Tumor Lysis Syndrome. <i>American Journal of Nursing</i> , 2004, 104, 49-52.	0.2	4
87	High-Grade Neuroendocrine Carcinoma of the Ampulla of Vater. <i>American Journal of Surgical Pathology</i> , 2005, 29, 588-594.	2.1	115
88	Correlation of HER2 Gene Amplification with Immunohistochemistry in Breast Cancer as Determined by a Novel Monoplex Polymerase Chain Reaction Assay. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2005, 13, 333-341.	0.6	11
89	B-Cell Specific Activation Protein Encoded by the PAX-5 Gene Is Commonly Expressed in Merkel Cell Carcinoma and Small Cell Carcinomas. <i>American Journal of Surgical Pathology</i> , 2005, 29, 687-692.	2.1	102
90	Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease. <i>British Journal of Cancer</i> , 2005, 93, 552-556.	2.9	263
91	Marked hyperuricemia with acute renal failure: need to consider occult malignancy and spontaneous tumour lysis syndrome. <i>International Journal of Clinical Practice</i> , 2005, 60, 364-366.	0.8	14
92	Virus Specific Immune Responses after Human Neoadjuvant Adenovirus-mediated Suicide Gene Therapy for Prostate Cancer. <i>European Urology</i> , 2005, 48, 153-161.	0.9	33
93	C-erb-B2 (HER2/neu) expression in synovial sarcoma of the head and neck. <i>Head and Neck</i> , 2005, 27, 883-892.	0.9	38
94	Lack of prognostic implications of HER-2/neu abnormalities in 345 stage I nonsmall cell carcinomas (NSCLC) and 207 stage I-III neuroendocrine tumours (NET) of the lung. <i>International Journal of Cancer</i> , 2005, 113, 101-108.	2.3	33
95	A novel NF- $\kappa$ B inhibitor DHMEQ selectively targets constitutive NF- $\kappa$ B activity and induces apoptosis of multiple myeloma cells in vitro and in vivo. <i>International Journal of Cancer</i> , 2005, 114, 32-38.	2.3	67
96	Immunotherapy of malignant ascites with trifunctional antibodies. <i>International Journal of Cancer</i> , 2005, 117, 435-443.	2.3	113

#	ARTICLE	IF	CITATIONS
97	Cisplatin activates Akt in small cell lung cancer cells and attenuates apoptosis by survivin upregulation. <i>International Journal of Cancer</i> , 2005, 117, 755-763.	2.3	93
98	Temozolomide Combined with Irradiation as Postoperative Treatment of Primary Glioblastoma Multiforme. <i>Strahlentherapie Und Onkologie</i> , 2005, 181, 372-377.	1.0	75
99	Treatment-related myelodysplastic syndrome after temozolomide for recurrent high-grade glioma. <i>Journal of Neuro-Oncology</i> , 2005, 71, 315-318.	1.4	68
100	HER1/EGFR tyrosine kinase inhibitors for the treatment of glioblastoma multiforme. <i>Journal of Neuro-Oncology</i> , 2005, 74, 77-86.	1.4	62
101	New anti-cancer strategies: Epigenetic therapies and biomarkers. <i>Frontiers in Bioscience - Landmark</i> , 2005, 10, 1897.	3.0	66
102	Use of Animal Models to Evaluate Signal Transduction Inhibitors As Modulators of Cytotoxic Therapy. , 2005, , 231-275.		0
103	ASH1 Gene Is a Specific Therapeutic Target for Lung Cancers with Neuroendocrine Features. <i>Cancer Research</i> , 2005, 65, 10680-10685.	0.4	115
104	Universality of J-Shaped and U-Shaped Dose-Response Relations as Emergent Properties of Stochastic Transition Systems. <i>Dose-Response</i> , 2005, 3, dose-response.0.	0.7	9
105	Genetic Profiling of Human Hepatocellular Carcinoma. <i>Seminars in Liver Disease</i> , 2005, 25, 125-132.	1.8	55
106	Allelotypes and Fluorescence In situ Hybridization Profiles of Poorly Differentiated Endocrine Carcinomas of Different Sites. <i>Clinical Cancer Research</i> , 2005, 11, 1765-1775.	3.2	21
107	Renal Involvement of Non-Hodgkin's Lymphoma and Its Prognostic Effect in Childhood. <i>Nephron Clinical Practice</i> , 2005, 100, c86-c91.	2.3	21
108	Renal Failure Associated with Cancer and Its Treatment: An Update. <i>Journal of the American Society of Nephrology: JASN</i> , 2005, 16, 151-161.	3.0	164
109	Epidermal growth factor receptor (EGFR)-related protein inhibits multiple members of the EGFR family in colon and breast cancer cells. <i>Molecular Cancer Therapeutics</i> , 2005, 4, 435-442.	1.9	111
110	The release of microparticles by apoptotic cells and their effects on macrophages. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2005, 10, 731-741.	2.2	127
111	Tolerability and safety of rituximab (MabThera®). <i>Cancer Treatment Reviews</i> , 2005, 31, 456-473.	3.4	442
112	Variation in transcriptional regulation of cyclin dependent kinase inhibitor p21waf1/cip1 among human bronchogenic carcinomas. <i>Molecular Cancer</i> , 2005, 4, 23.	7.9	130
113	Detection of molecular targets on the surface of CD34+/CD38 <sup>-</sup> stem cells in various myeloid malignancies. <i>Leukemia and Lymphoma</i> , 2006, 47, 207-222.	0.6	140
114	Abbreviated Rasburicase Dosing for the Prevention and Treatment of Hyperuricemia in Adults at Risk for Tumor Lysis Syndrome. <i>Supportive Cancer Therapy</i> , 2006, 3, 178-182.	0.3	11

#	ARTICLE	IF	CITATIONS
115	Bortezomib-Induced Tumor Lysis Syndrome in Multiple Myeloma. <i>Clinical Lymphoma and Myeloma</i> , 2006, 7, 233-235.	1.4	46
116	Multipotent, Dedifferentiated Cancer Stem-like Cells from Brain Gliomas. <i>Stem Cells and Development</i> , 2006, 15, 423-435.	1.1	52
117	The mechanism of methylselenocysteine and docetaxel synergistic activity in prostate cancer cells. <i>Molecular Cancer Therapeutics</i> , 2006, 5, 2540-2548.	1.9	31
118	Exploiting the role of O6-methylguanine-DNA-methyltransferase (MGMT) in cancer therapy. <i>Current Opinion in Pharmacology</i> , 2006, 6, 355-363.	1.7	86
119	Epidermal growth factor receptor inhibition for the treatment of glioblastoma multiforme and other malignant brain tumours. <i>Cancer Treatment Reviews</i> , 2006, 32, 74-89.	3.4	157
120	Safety and pharmacokinetics of temozolomide using a dose-escalation, metronomic schedule in recurrent paediatric brain tumours. <i>European Journal of Cancer</i> , 2006, 42, 2335-2342.	1.3	83
121	Acute complications. , 2006, , 709-749.		5
124	Small Cell Carcinoma of the Prostate: An Immunohistochemical Study. <i>American Journal of Surgical Pathology</i> , 2006, 30, 705-712.	2.1	190
125	Phase I/II Study of Weekly Docetaxel and Vinblastine in the Treatment of Metastatic Hormone-Refractory Prostate Carcinoma. <i>Cancer Journal (Sudbury, Mass )</i> , 2006, 12, 299-304.	1.0	11
126	Regression of Grade III Astrocytoma During the Treatment of CML with Imatinib Mesylate. <i>American Journal of Therapeutics</i> , 2006, 13, 458-459.	0.5	4
127	Sequential combinations of flavopiridol and docetaxel inhibit prostate tumors, induce apoptosis, and decrease angiogenesis in the G1 <sup>3</sup> /T-15 transgenic mouse model of prostate cancer. <i>Prostate</i> , 2006, 66, 1487-1497.	1.2	18
128	Quantifying Potential Health Impacts of Cadmium in Cigarettes on Smoker Risk of Lung Cancer: A Portfolio of Mechanisms Approach. <i>Risk Analysis</i> , 2006, 26, 1581-1599.	1.5	14
129	Docetaxel induces apoptosis in hormone refractory prostate carcinomas during multiple treatment cycles. <i>British Journal of Cancer</i> , 2006, 94, 1592-1598.	2.9	76
130	DHMEQ, a new NF- $\kappa$ B inhibitor, induces apoptosis and enhances fludarabine effects on chronic lymphocytic leukemia cells. <i>Leukemia</i> , 2006, 20, 800-806.	3.3	44
131	Combined microarray analysis of small cell lung cancer reveals altered apoptotic balance and distinct expression signatures of MYC family gene amplification. <i>Oncogene</i> , 2006, 25, 130-138.	2.6	165
132	Potent inhibition of small-cell lung cancer cell growth by simvastatin reveals selective functions of Ras isoforms in growth factor signalling. <i>Oncogene</i> , 2006, 25, 877-887.	2.6	107
133	Comparative and integrative functional genomics of HCC. <i>Oncogene</i> , 2006, 25, 3801-3809.	2.6	109
134	Metabolic emergencies. <i>Critical Reviews in Oncology/Hematology</i> , 2006, 58, 79-89.	2.0	56

#	ARTICLE	IF	CITATIONS
135	The growth factor independence-1 transcription factor: New functions and new insights. <i>Critical Reviews in Oncology/Hematology</i> , 2006, 59, 85-97.	2.0	45
136	Concomitant bone marrow metastasis of a glioblastoma multiforme revealed at the diagnosis. <i>Acta Neurochirurgica</i> , 2006, 148, 997-1000.	0.9	18
137	Quantification of urinary allantoin by capillary zone electrophoresis during recombinant urate oxydase (rasburicase) therapy. <i>Clinical Biochemistry</i> , 2006, 39, 86-90.	0.8	10
138	Use of bacteria in anti-cancer therapies. <i>BioEssays</i> , 2006, 28, 84-94.	1.2	72
139	Enhancement of glioblastoma cell killing by combination treatment with temozolomide and tamoxifen or hypericin. <i>Neurosurgical Focus</i> , 2006, 20, E20.	1.0	34
140	The Potential of BORIS Detected in the Leukocytes of Breast Cancer Patients as an Early Marker of Tumorigenesis. <i>Clinical Cancer Research</i> , 2006, 12, 5978-5986.	3.2	41
141	Calcium-dependent growth regulation of small cell lung cancer cells by neuropeptides. <i>Endocrine-Related Cancer</i> , 2006, 13, 1069-1084.	1.6	21
142	Clinical Significance of p16INK4A and p53 Overexpression in Endocrine Tumors of the Gastrointestinal Tract. <i>American Journal of Clinical Pathology</i> , 2006, 126, 856-865.	0.4	13
143	Sequential combination of flavopiridol and docetaxel reduces the levels of X-linked inhibitor of apoptosis and AKT proteins and stimulates apoptosis in human LNCaP prostate cancer cells. <i>Molecular Cancer Therapeutics</i> , 2006, 5, 1216-1226.	1.9	27
144	Recombinant Urate Oxidase (Rasburicase) for the Prevention and Treatment of Tumor Lysis Syndrome in Patients with Hematologic Malignancies. <i>Acta Haematologica</i> , 2006, 115, 35-38.	0.7	42
145	TUMOR LYSIS SYNDROME IN CHILDREN WITH NON-HODGKIN LYMPHOMA. <i>Pediatric Hematology and Oncology</i> , 2006, 23, 65-70.	0.3	19
146	The management of tumor lysis syndrome. <i>Nature Clinical Practice Oncology</i> , 2006, 3, 438-447.	4.3	115
147	Coexpression of Fragile Histidine Triad and c-kit Is Relevant for Prediction of Survival in Patients with Small Cell Lung Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2006, 15, 2232-2238.	1.1	5
148	Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT. <i>Haematologica</i> , 2007, 92, 1451-1459.	1.7	92
149	Assessment of apoptosis-inducing effects of docetaxel combined with the proteasome inhibitor PS-341 in human lung cancer cells. <i>Cancer Biology and Therapy</i> , 2007, 6, 749-754.	1.5	8
150	Molecular Pathogenesis of Early-Stage Non-small Cell Lung Cancer and a Proposal for Tissue Banking to Facilitate Identification of New Biomarkers. <i>Journal of Thoracic Oncology</i> , 2007, 2, S128-S135.	0.5	19
151	Oncogenic cooperation and coamplification of developmental transcription factor genes in lung cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 16663-16668.	3.3	203
152	Platelet-derived growth factor receptor- $\alpha$ : a novel therapeutic target in human hepatocellular cancer. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 1932-1941.	1.9	96

#	ARTICLE	IF	CITATIONS
153	Combination of non-viral connexin 43 gene therapy and docetaxel inhibits the growth of human prostate cancer in mice. <i>International Journal of Oncology</i> , 2007, , .	1.4	8
154	The Complex Role of AR Signaling After Cytotoxic Insult: Implications for Cell Cycle Based Chemotherapeutics. <i>Cell Cycle</i> , 2007, 6, 1307-1313.	1.3	32
155	The Impact of Genetic Markers on the Diagnosis of Lung Cancer: A Current Perspective. <i>Journal of Thoracic Oncology</i> , 2007, 2, 1044-1051.	0.5	28
156	Potential of the anti-tumour effect of docetaxel by conjugated linoleic acids (CLAs) in breast cancer cells in vitro. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2007, 77, 87-96.	1.0	29
157	Successful Treatment of Acute Tumor Lysis Syndrome in a Dog with Multicentric Lymphoma. <i>Journal of Veterinary Internal Medicine</i> , 2007, 21, 1401-1404.	0.6	17
158	Metastasis of Prostate Cancer. <i>Cancer Metastasis - Biology and Treatment</i> , 2007, , .	0.1	4
159	Molecular analysis of deletions in human chromosome 3p21 and the role of resident cancer genes in disease. <i>Briefings in Functional Genomics &amp; Proteomics</i> , 2007, 6, 19-39.	3.8	63
160	Elevated risk of squamous-cell carcinoma of the lung in heavy smokers carrying the variant alleles of the TP53 Arg72Pro and p21 Ser31Arg polymorphisms. <i>Lung Cancer</i> , 2007, 55, 25-34.	0.9	41
161	Differences between small-cell lung cancer and non-small-cell lung cancer among tobacco smokers. <i>Lung Cancer</i> , 2007, 56, 161-166.	0.9	26
162	Distilling the Past – Envisioning the Future. , 2008, , 355-397.		0
163	Translational Bioinformatics: At the Interface of Genomics and Quantitative Genetics. <i>Crop Science</i> , 2007, 47, S-32.	0.8	2
164	Immunohistochemical Study of C-erbB-2 and VEGF Expression in Non-Small Cell Lung Cancer. <i>Tuberculosis and Respiratory Diseases</i> , 2007, 62, 43.	0.7	0
165	The interactive transcript abundance index [c-myc*p73]/[p21*Bcl-2] correlates with baseline level of apoptosis and response to CPT-11 in human bronchogenic carcinoma cell lines. <i>International Journal of Oncology</i> , 2007, 30, 1553-60.	1.4	1
166	Inactivation of RASSF2A by promoter methylation correlates with lymph node metastasis in nasopharyngeal carcinoma. <i>International Journal of Cancer</i> , 2007, 120, 32-38.	2.3	86
167	Expression of p21 inhibits cell cycle progression and suppresses tumorigenicity of lung cancer cells. <i>International Journal of Cancer</i> , 2008, 122, 1512-1520.	2.3	20
168	Epigenetic inactivation of the deleted in lung and esophageal cancer 1 gene in nasopharyngeal carcinoma. <i>Genes Chromosomes and Cancer</i> , 2007, 46, 171-180.	1.5	54
169	Prognostic markers in triple-negative breast cancer. <i>Cancer</i> , 2007, 109, 25-32.	2.0	1,091
170	Tumor lysis syndrome in elderly. <i>Critical Reviews in Oncology/Hematology</i> , 2007, 64, 31-42.	2.0	25

#	ARTICLE	IF	CITATIONS
171	The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. <i>Oncogene</i> , 2007, 26, 6469-6487.	2.6	867
172	IL-1 $\beta$ independent induction of NF- $\kappa$ B and its inhibition by DHMEQ in Hodgkin/Reed-Sternberg cells. <i>Laboratory Investigation</i> , 2007, 87, 372-382.	1.7	22
173	Pre-clinical and clinical evaluation of estramustine, docetaxel and thalidomide combination in androgen-independent prostate cancer. <i>BJU International</i> , 2007, 99, 1047-1055.	1.3	45
174	Small Cell Carcinomas of the Gastrointestinal Tract: Clinicopathological Features and Treatment Approach. <i>Seminars in Oncology</i> , 2007, 34, 43-50.	0.8	85
175	Docetaxel, low-dose estramustine, and doxifluridine in hormone-refractory metastatic prostate cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2007, 61, 53-61.	1.1	4
176	Mutational analysis of ErbB2 intracellular localization. <i>Histochemistry and Cell Biology</i> , 2007, 128, 473-483.	0.8	2
177	Lack of association of fragile histidine triad (FHIT) polymorphisms with lung cancer in the Korean population. <i>Journal of Human Genetics</i> , 2007, 52, 668-674.	1.1	0
178	Targeted therapy for small cell lung cancer. <i>Targeted Oncology</i> , 2007, 2, 89-97.	1.7	2
179	Signal Transduction in Transgenic Mouse Models of Human Breast Cancer—Implications for Human Breast Cancer. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2008, 13, 323-335.	1.0	45
180	Multimodality imaging of the HER-kinase axis in cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2008, 35, 186-208.	3.3	109
181	Tyrosine1248-phosphorylated HER2 expression and HER2 gene amplification in female invasive ductal carcinomas. <i>Breast Cancer</i> , 2008, 15, 231-240.	1.3	20
182	Association study of TP53 polymorphisms with lung cancer in a Korean population. <i>Journal of Human Genetics</i> , 2008, 53, 508-514.	1.1	22
183	Small cell carcinoma of the cervix: a case report. <i>Archives of Gynecology and Obstetrics</i> , 2008, 277, 367-370.	0.8	7
184	RANKL inhibition is an effective adjuvant for docetaxel in a prostate cancer bone metastases model. <i>Prostate</i> , 2008, 68, 820-829.	1.2	25
185	Evidence of a novel docetaxel sensitizer, garlic-derived S-allylmercaptocysteine, as a treatment option for hormone refractory prostate cancer. <i>International Journal of Cancer</i> , 2008, 122, 1941-1948.	2.3	32
186	Differential subcellular localisation of the tumour suppressor protein LIMD1 in breast cancer correlates with patient survival. <i>International Journal of Cancer</i> , 2008, 123, 2247-2253.	2.3	21
187	Antiadult T-cell leukemia effects of brown algae fucoxanthin and its deacetylated product, fucoxanthinol. <i>International Journal of Cancer</i> , 2008, 123, 2702-2712.	2.3	116
188	Cutaneous T-cell lymphoma-associated lung cancers show chromosomal aberrations differing from primary lung cancer. <i>Genes Chromosomes and Cancer</i> , 2008, 47, 107-117.	1.5	15

#	ARTICLE	IF	CITATIONS
190	Cigarette smoke induces endoplasmic reticulum stress and the unfolded protein response in normal and malignant human lung cells. <i>BMC Cancer</i> , 2008, 8, 229.	1.1	146
191	The immunocytokine scFv23/TNF targeting HER-2/neu induces synergistic cytotoxic effects with 5-fluorouracil in TNF-resistant pancreatic cancer cell lines. <i>Biochemical Pharmacology</i> , 2008, 75, 836-846.	2.0	24
192	TRAIL-induced survival and proliferation of SCLC cells is mediated by ERK and dependent on TRAIL-R2/DR5 expression in the absence of caspase-8. <i>Lung Cancer</i> , 2008, 60, 355-365.	0.9	39
193	Small Cell, Big Problem! Stem Cells, Root Cause?. <i>Clinical Lung Cancer</i> , 2008, 9, 252-253.	1.1	6
194	Small Cell Lung Cancer. <i>Mayo Clinic Proceedings</i> , 2008, 83, 355-367.	1.4	412
195	Consensus conference on the management of tumor lysis syndrome. <i>Haematologica</i> , 2008, 93, 1877-1885.	1.7	125
196	Alterations in the p16INK4a/Cyclin D1/RB Pathway in Gastrointestinal Tract Endocrine Tumors. <i>American Journal of Clinical Pathology</i> , 2008, 130, 535-542.	0.4	19
197	Role of AIB1 for Tamoxifen Resistance in Estrogen Receptor-Positive Breast Cancer Cells. <i>Oncology</i> , 2008, 75, 159-168.	0.9	43
198	Comparative Genomic Hybridisation Arrays: High-Throughput Tools to Determine Targeted Therapy in Breast Cancer. <i>Pathobiology</i> , 2008, 75, 63-74.	1.9	17
199	Fas-mediated killing of primary prostate cancer cells is increased by mitoxantrone and docetaxel. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 3018-3028.	1.9	23
200	Molecular Alterations in Spontaneous Sputum of Cancer-Free Heavy Smokers: Results from a Large Screening Program. <i>Clinical Cancer Research</i> , 2008, 14, 1913-1919.	3.2	52
201	Tumor Suppressor FUS1 Signaling Pathway. <i>Journal of Thoracic Oncology</i> , 2008, 3, 327-330.	0.5	69
202	Novel complex t(V;9;22) rearrangements in three cases with chronic myeloid leukemia and a rare translocation in a case with classical Philadelphia chromosome. <i>Oncology Reports</i> , 0, , .	1.2	6
203	Posttranscription Regulation of Prostate Cancer Growth. <i>Cancer Journal (Sudbury, Mass )</i> , 2008, 14, 46-53.	1.0	16
204	SÃndrome de lise tumoral: uma revisÃ£o abrangente da literatura. <i>Revista Brasileira De Terapia Intensiva</i> , 2008, 20, 278-285.	0.1	6
206	Molecular Basis of Pulmonary Disease. , 2009, , 305-364.		4
207	Potential Role of Thymosin- $\alpha$ 1 Adjuvant Therapy for Glioblastoma. <i>Journal of Oncology</i> , 2009, 2009, 1-11.	0.6	9
208	Alterations in the Noxa/Mcl-1 axis determine sensitivity of small cell lung cancer to the BH3 mimetic ABT-737. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 883-892.	1.9	63

#	ARTICLE	IF	CITATIONS
209	Preventive Effects of Bexarotene and Budesonide in a Genetically Engineered Mouse Model of Small Cell Lung Cancer. <i>Cancer Prevention Research</i> , 2009, 2, 1059-1064.	0.7	26
210	Molecular mechanism of trifluoperazine induces apoptosis in human A549 lung adenocarcinoma cell lines. <i>Molecular Medicine Reports</i> , 2009, 2, 811-7.	1.1	22
211	<i>d</i>-Limonene sensitizes docetaxel-induced cytotoxicity in human prostate cancer cells: Generation of reactive oxygen species and induction of apoptosis. <i>Journal of Carcinogenesis</i> , 2009, 8, 9.	2.5	93
212	AKT/mTOR Pathway Activation and BCL-2 Family Proteins Modulate the Sensitivity of Human Small Cell Lung Cancer Cells to RAD001. <i>Clinical Cancer Research</i> , 2009, 15, 1277-1287.	3.2	85
213	Oncological emergencies. , 2009, , 61-65.		0
214	Retinoblastoma Tumor Suppressor Gene Expression Determines the Response to Sequential Flavopiridol and Doxorubicin Treatment in Small-Cell Lung Carcinoma. <i>Clinical Cancer Research</i> , 2009, 15, 1232-1240.	3.2	9
215	Low level anti-Hu reactivity: A risk marker for small cell lung cancer?. <i>Cancer Detection and Prevention</i> , 2009, 32, 292-299.	2.1	10
216	<i>TP53</i> Arg72Pro polymorphism and lung cancer risk: A meta-analysis. <i>International Journal of Cancer</i> , 2009, 125, 2903-2911.	2.3	30
217	Phase II trial of neoadjuvant docetaxel and gefitinib followed by radical prostatectomy in patients with high-risk, locally advanced prostate cancer. <i>Cancer</i> , 2009, 115, 784-791.	2.0	44
218	Pegylated liposomal doxorubicin and trastuzumab as 1st and 2nd line therapy in her2/neu positive metastatic breast cancer: a multicenter phase II trial. <i>Breast Cancer Research and Treatment</i> , 2009, 117, 591-598.	1.1	37
219	Quantitative cell signalling analysis reveals down-regulation of MAPK pathway activation in colorectal cancer. <i>Journal of Pathology</i> , 2009, 218, 514-519.	2.1	60
220	Novel complex translocation involving 5 different chromosomes in a chronic myeloid leukemia with Philadelphia chromosome: a case report. <i>Molecular Cytogenetics</i> , 2009, 2, 21.	0.4	10
221	Tumor lysis syndrome after transcatheter arterial infusion of cisplatin and embolization therapy for liver metastases of melanoma. <i>International Journal of Dermatology</i> , 2009, 48, 763-767.	0.5	18
222	The retinoblastoma gene Rb and its family member p130 suppress lung adenocarcinoma induced by oncogenic K-Ras. <i>Oncogene</i> , 2009, 28, 1393-1399.	2.6	44
223	The Role of Mutation and Epimutation in the Development of Human Disease. <i>Molecular Pathology Library</i> , 2009, , 41-54.	0.1	2
224	Preparation and the Influencing Factors of Timozolomide Liposomes. <i>Artificial Cells, Blood Substitutes, and Biotechnology</i> , 2009, 37, 279-282.	0.9	2
225	Deficiency of a potential 3p21.3 tumor suppressor gene UBE1L (UBA7) does not accelerate lung cancer development in K-rasLA2 mice. <i>Lung Cancer</i> , 2009, 63, 194-200.	0.9	11
226	Induction of anti-tumor immunity by trifunctional antibodies in patients with peritoneal carcinomatosis. <i>Journal of Experimental and Clinical Cancer Research</i> , 2009, 28, 18.	3.5	45

#	ARTICLE	IF	CITATIONS
227	Association of C3435T Single-Nucleotide Polymorphism of <i>MDR1</i> Gene with Breast Cancer in an Iranian Population. <i>DNA and Cell Biology</i> , 2009, 28, 259-263.	0.9	31
228	Neuroendocrine Cancer-Specific Up-Regulating Mechanism of Insulin-Like Growth Factor Binding Protein-2 in Small Cell Lung Cancer. <i>American Journal of Pathology</i> , 2009, 175, 976-987.	1.9	27
229	Microarray-Based Comparative Genomic Hybridization. , 0, , 135-161.		0
230	Synergistic effects of tethered growth factors and adhesion ligands on DNA synthesis and function of primary hepatocytes cultured on soft synthetic hydrogels. <i>Biomaterials</i> , 2010, 31, 4657-4671.	5.7	43
231	Fragile histidine triad protein: structure, function, and its association with tumorigenesis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2010, 136, 333-350.	1.2	29
232	Analysis of exhaled breath for screening of lung cancer patients. <i>Memo - Magazine of European Medical Oncology</i> , 2010, 3, 106-112.	0.3	35
233	Molecular pathology in adult gliomas: diagnostic, prognostic, and predictive markers. <i>Lancet Neurology</i> , The, 2010, 9, 717-726.	4.9	251
234	A rare case of chronic myeloid leukemia with secondary chromosomal changes including partial trisomy 17q21 to 17qter and partial monosomy of 16p13.3. <i>Molecular Cytogenetics</i> , 2010, 3, 6.	0.4	6
235	Rh2 or its aglycone aPPD in combination with docetaxel for treatment of prostate cancer. <i>Prostate</i> , 2010, 70, 1437-1447.	1.2	29
236	p66Shc restrains Ras hyperactivation and suppresses metastatic behavior. <i>Oncogene</i> , 2010, 29, 5559-5567.	2.6	53
237	Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG-014699. <i>British Journal of Cancer</i> , 2010, 103, 1588-1596.	2.9	58
238	A cyclic-RGD-BioShuttle functionalized with TMZ by DAR <sub>inv</sub> â€œClick Chemistryâ€ targeted to Î± <sub>v</sub> Î² <sub>3</sub> integrin for therapy. <i>International Journal of Medical Sciences</i> , 2010, 7, 326-339.	1.1	18
239	Actinomycin D Decreases Mcl-1 Expression and Acts Synergistically with ABT-737 against Small Cell Lung Cancer Cell Lines. <i>Clinical Cancer Research</i> , 2010, 16, 4392-4400.	3.2	37
240	Loss of p130 Accelerates Tumor Development in a Mouse Model for Human Small-Cell Lung Carcinoma. <i>Cancer Research</i> , 2010, 70, 3877-3883.	0.4	201
241	Cigarette Smoking and Colorectal Cancer Risk by Molecularly Defined Subtypes. <i>Journal of the National Cancer Institute</i> , 2010, 102, 1012-1022.	3.0	261
242	Interphase Cytogenetics of Sputum Cells for the Early Detection of Lung Carcinogenesis. <i>Cancer Prevention Research</i> , 2010, 3, 416-419.	0.7	8
243	The molecular pathogenesis of small cell lung cancer. <i>Cancer Biology and Therapy</i> , 2010, 10, 1-10.	1.5	65
245	Spontaneous Acute Tumor Lysis Syndrome as a Cause of Early Deaths in Short-Term Carcinogenicity Studies Using <i>p53</i> <sup>+/â€</sup> Mice. <i>Veterinary Pathology</i> , 2010, 47, 719-724.	0.8	14

#	ARTICLE	IF	CITATIONS
246	Approaches for Administering Chemotherapy in the Intensive Care Unit. <i>Current Drug Safety</i> , 2010, 5, 22-32.	0.3	8
248	The combination of Young's syndrome and small cell lung cancer—A spiky connection?. <i>Lung Cancer</i> , 2010, 67, 372-375.	0.9	0
249	Elevated expression of phosphorylated c-Jun NH2-terminal kinase in basal-like and "triple-negative" breast cancers. <i>Human Pathology</i> , 2010, 41, 401-406.	1.1	27
250	Prognostic significance of acute renal injury in acute tumor lysis syndrome. <i>Leukemia and Lymphoma</i> , 2010, 51, 221-227.	0.6	87
251	The Effect of Adenovirus-Mediated Gene Expression of FHIT in Small Cell Lung Cancer Cells. <i>Cancer Investigation</i> , 2011, 29, 683-691.	0.6	8
252	Nuclear factor I/B is an oncogene in small cell lung cancer. <i>Genes and Development</i> , 2011, 25, 1470-1475.	2.7	142
253	Molecular Biology of Lung Cancer: Clinical Implications. <i>Clinics in Chest Medicine</i> , 2011, 32, 703-740.	0.8	194
254	Small-cell lung cancer-associated autoantibodies: potential applications to cancer diagnosis, early detection, and therapy. <i>Molecular Cancer</i> , 2011, 10, 33.	7.9	71
255	Complex translocation involving four chromosomes in a novel Philadelphia-positive chronic myeloid leukemia case. <i>Oncology Letters</i> , 2011, 2, 273-276.	0.8	1
256	Bmi1 regulates cell fate via tumor suppressor <i>WWOX</i> repression in small cell lung cancer cells. <i>Cancer Science</i> , 2011, 102, 983-990.	1.7	26
257	Acute hyperammonemia after L-asparaginase administration in a dog. <i>Journal of Veterinary Emergency and Critical Care</i> , 2011, 21, 673-678.	0.4	6
258	The staging and treatment of multicentric high-grade lymphoma in dogs: A review of recent developments and future prospects. <i>Veterinary Journal</i> , 2011, 188, 34-38.	0.6	55
259	Effects of AZD1152, a selective Aurora B kinase inhibitor, on Burkitt's and Hodgkin's lymphomas. <i>Biochemical Pharmacology</i> , 2011, 81, 1106-1115.	2.0	19
260	Smoking and the Association of Advanced Colorectal Neoplasia in an Asymptomatic Average Risk Population: Analysis of Exposure and Anatomical Location in Men and Women. <i>Digestive Diseases and Sciences</i> , 2011, 56, 3616-3623.	1.1	28
261	The $\beta_2$ -adrenergic receptor and Her2 comprise a positive feedback loop in human breast cancer cells. <i>Breast Cancer Research and Treatment</i> , 2011, 125, 351-362.	1.1	108
262	Molecular oncology of lung cancer. <i>General Thoracic and Cardiovascular Surgery</i> , 2011, 59, 527-537.	0.4	60
263	Effect of HER2 status on risk of recurrence in women with small, node-negative breast tumours. <i>British Journal of Surgery</i> , 2011, 98, 1561-1565.	0.1	8
264	Identification of a core member of the SWI/SNF complex, BAF155/SMARCC1, as a human tumor suppressor gene. <i>Epigenetics</i> , 2011, 6, 1444-1453.	1.3	47

#	ARTICLE	IF	CITATIONS
265	Polymorphisms in miRNA binding site: new insight into small cell lung cancer susceptibility. <i>Acta Pharmacologica Sinica</i> , 2011, 32, 1191-1192.	2.8	4
266	Small HER2-positive, node-negative breast cancer: who should receive systemic adjuvant treatment?. <i>Annals of Oncology</i> , 2011, 22, 17-23.	0.6	27
267	Multimode optical imaging for translational chemotherapy: in vivo tumor detection and delineation by targeted gallium corroles. <i>Proceedings of SPIE</i> , 2011, 7902, .	0.8	4
268	Mutant p53 cooperates with ETS2 to promote etoposide resistance. <i>Genes and Development</i> , 2012, 26, 830-845.	2.7	164
269	A framework for identification of actionable cancer genome dependencies in small cell lung cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 17034-17039.	3.3	167
270	Molecular Markers with Predictive and Prognostic Relevance in Lung Cancer. <i>Lung Cancer International</i> , 2012, 2012, 1-12.	1.2	17
271	Combination Effects of Docetaxel and Doxorubicin in Hormone-Refractory Prostate Cancer Cells. <i>Biochemistry Research International</i> , 2012, 2012, 1-10.	1.5	62
272	Tumor Lysis Syndrome: A Systematic Review of Case Series and Case Reports. <i>Postgraduate Medicine</i> , 2012, 124, 92-101.	0.9	36
273	Fluorescent Dye Conjugates for Optical Imaging of Cancer. , 2012, , 451-482.		0
274	A chronic myeloid leukemia case with a unique variant Philadelphia translocation: t(9;22;21)(q34;q11;p12). <i>Oncology Letters</i> , 2012, 3, 1027-1029.	0.8	12
275	Canine tumors: a spontaneous animal model of human carcinogenesis. <i>Translational Research</i> , 2012, 159, 165-172.	2.2	208
276	Allogeneic Hematopoietic Stem Cell Transplantation for Philadelphia-Positive Acute Lymphoblastic Leukemia in Children and Adolescents: A Retrospective Multicenter Study of the Italian Association of Pediatric Hematology and Oncology (AIEOP). <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 852-860.	2.0	18
277	Docetaxel. <i>Drugs</i> , 2012, 72, 1559-1577.	4.9	46
278	Frequent methylation and oncogenic role of microRNA-34b/c in small-cell lung cancer. <i>Lung Cancer</i> , 2012, 76, 32-38.	0.9	102
279	Integrin-Associated CD151 Drives ErbB2-Evoked Mammary Tumor Onset and Metastasis. <i>Neoplasia</i> , 2012, 14, 678-IN3.	2.3	69
280	Animal Models for Breast Cancer Prevention Research. , 2012, , 497-526.		1
281	Serous Effusions. , 2012, , .		9
282	Cancer Epigenetics. <i>Methods in Molecular Biology</i> , 2012, , .	0.4	5

#	ARTICLE	IF	CITATIONS
283	HER-2 gene amplification by fluorescence in situ hybridization (FISH) compared with immunohistochemistry (IHC) in breast cancer: a study of 528 equivocal cases. <i>Breast Cancer Research and Treatment</i> , 2012, 134, 743-749.	1.1	17
284	Impact of Genetic Targets on Cancer Therapy. <i>Advances in Experimental Medicine and Biology</i> , 2013, 779, v-vi.	0.8	1
285	The influence of genetic polymorphisms in MDR1 gene on breast cancer risk factors in Chinese. <i>Medical Oncology</i> , 2013, 30, 601.	1.2	2
286	Diagnostic Pathology of Pleuropulmonary Neoplasia. , 2013, , .		8
287	The DNA methylation landscape of small cell lung cancer suggests a differentiation defect of neuroendocrine cells. <i>Oncogene</i> , 2013, 32, 3559-3568.	2.6	67
288	Genetic alterations defining NSCLC subtypes and their therapeutic implications. <i>Lung Cancer</i> , 2013, 82, 179-189.	0.9	262
289	The association between genetic variant of MDR1 gene and breast cancer risk factors in Chinese women. <i>International Immunopharmacology</i> , 2013, 17, 88-91.	1.7	4
290	A rare case of primary malignant small cell carcinoma combined with urothelial cell carcinoma in the ureter. <i>World Journal of Surgical Oncology</i> , 2013, 11, 181.	0.8	15
291	Genome-wide identification of genes with amplification and/or fusion in small cell lung cancer. <i>Genes Chromosomes and Cancer</i> , 2013, 52, 802-816.	1.5	106
292	Molecular Pathology of Lung Cancer. , 2013, , 443-459.		0
293	Targeting the Phosphoinositide 3-Kinase p110- $\alpha$ Isoform Impairs Cell Proliferation, Survival, and Tumor Growth in Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 96-105.	3.2	30
294	Expression of the coxsackie adenovirus receptor in neuroendocrine lung cancers and its implications for oncolytic adenoviral infection. <i>Cancer Gene Therapy</i> , 2013, 20, 25-32.	2.2	19
295	A Drug Repositioning Approach Identifies Tricyclic Antidepressants as Inhibitors of Small Cell Lung Cancer and Other Neuroendocrine Tumors. <i>Cancer Discovery</i> , 2013, 3, 1364-1377.	7.7	366
296	Investigation on MDR1 gene polymorphisms and its relationship with breast cancer risk factors in Chinese women. <i>Medical Oncology</i> , 2013, 30, 375.	1.2	6
297	<sc>POU</sc> domain transcription factor <sc>BRN</sc>2 is crucial for expression of <sc>ASCL</sc>1, <sc>ND</sc>1 and neuroendocrine marker molecules and cell growth in small cell lung cancer. <i>Pathology International</i> , 2013, 63, 158-168.	0.6	47
298	The Aurora Kinases Inhibitor VE-665 is a Novel Treatment for Glioblastoma Multiforme. <i>Oncology</i> , 2013, 84, 326-335.	0.9	10
299	Small-Cell Lung Cancer: An Update on Targeted Therapies. <i>Advances in Experimental Medicine and Biology</i> , 2013, 779, 385-404.	0.8	40
300	Cell of origin of lung cancer. <i>Journal of Carcinogenesis</i> , 2013, 12, 6.	2.5	55

#	ARTICLE	IF	CITATIONS
301	Factors predicting temozolomide induced clinically significant acute hematologic toxicity in patients with high-grade gliomas: A clinical audit. <i>Clinical Neurology and Neurosurgery</i> , 2013, 115, 1814-1819.	0.6	26
302	Association analysis between MDR1 genetic variant and breast cancer risk factors in Chinese Han population. <i>Medical Oncology</i> , 2013, 30, 683.	1.2	1
303	The Small Cell Lung Cancer-Specific Isoform of RE1-Silencing Transcription Factor (REST) Is Regulated By Neural-Specific Ser/Arg Repeat-Related Protein of 100 kDa (nSR100). <i>Molecular Cancer Research</i> , 2013, 11, 1258-1268.	1.5	27
304	The effect of imatinib mesylate on the proliferation, invasive ability, and radiosensitivity of retinoblastoma cell lines. <i>Eye</i> , 2013, 27, 92-99.	1.1	9
305	Insulin-Like Growth Factor 1 Receptor as a Therapeutic Target in Ewing Sarcoma: Lack of Consistent Upregulation or Recurrent Mutation and a Review of the Clinical Trial Literature. <i>Sarcoma</i> , 2013, 2013, 1-12.	0.7	22
306	Selective Tropism of Seneca Valley Virus for Variant Subtype Small Cell Lung Cancer. <i>Journal of the National Cancer Institute</i> , 2013, 105, 1059-1065.	3.0	106
307	Facts and fiction: premalignant lesions of lung tissues. <i>Pathology</i> , 2013, 45, 305-315.	0.3	26
308	Apoptotic effects of the tyrosine kinase inhibitor, masitinib mesylate, on canine osteosarcoma cells. <i>Anti-Cancer Drugs</i> , 2013, 24, 519-526.	0.7	15
309	A new t(9;11;20;22)(q34;p11.2;q11.21;q11) in a Philadelphia-positive chronic myeloid leukemia case. <i>Oncology Letters</i> , 2013, 5, 605-608.	0.8	14
310	The Role of PET/CT and SPECT/CT in Oncology Drug Development. <i>Current Molecular Imaging</i> , 2013, 2, 42-52.	0.7	2
311	Cutaneous metastatic adenocarcinoma complicated by spontaneous tumor lysis syndrome: A case report. <i>Oncology Letters</i> , 2014, 8, 905-907.	0.8	8
312	Prognostic Markers in Small Cell Lung Cancer. <i>Current Cancer Therapy Reviews</i> , 2014, 10, 39-46.	0.2	2
313	Cell cycle inhibitors for the treatment of NSCLC. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 991-1004.	0.9	15
314	Gene mutations in small-cell lung cancer (SCLC): Results of a panel of 6 genes in a cohort of Italian patients. <i>Lung Cancer</i> , 2014, 86, 324-328.	0.9	29
315	Natural Products from Terrestrial Microbial Organisms with Cytotoxic Cell Cycle Inhibitors. , 2014, , 147-208.		0
316	MYCN and survivin cooperatively contribute to malignant transformation of fibroblasts. <i>Carcinogenesis</i> , 2014, 35, 479-488.	1.3	10
317	Role of nontoxigenic <i>Clostridium novyi</i> in solid tumor therapy. <i>Reviews in Medical Microbiology</i> , 2014, 25, 71-76.	0.4	7
318	Taxanes. <i>Anti-Cancer Drugs</i> , 2014, 25, 512-521.	0.7	25

#	ARTICLE	IF	CITATIONS
319	A MicroRNA Signature Predicts Survival in Early Stage Small-Cell Lung Cancer Treated with Surgery and Adjuvant Chemotherapy. PLoS ONE, 2014, 9, e91388.	1.1	39
320	Identification of an antibody fragment specific for androgen-dependent prostate cancer cells. BMC Biotechnology, 2014, 14, 81.	1.7	13
321	Activity of the Monocarboxylate Transporter 1 Inhibitor AZD3965 in Small Cell Lung Cancer. Clinical Cancer Research, 2014, 20, 926-937.	3.2	256
322	Diet modulation is an effective complementary agent in preventing and treating breast cancer lung metastasis. Clinical and Experimental Metastasis, 2014, 31, 625-638.	1.7	4
323	Rapid Progression of Anemia Related to Tumor-lysis Syndrome Associated with Bortezomib Treatment in Myeloma Patients. Japanese Journal of Clinical Oncology, 2014, 44, 435-441.	0.6	6
324	Chitosan cross-linked docetaxel loaded EGF receptor targeted nanoparticles for lung cancer cells. International Journal of Biological Macromolecules, 2014, 69, 532-541.	3.6	42
325	Comparison between taxane-based chemotherapy with conventional surgery-based therapy for cutaneous angiosarcoma: a single-center experience. Journal of Dermatological Treatment, 2014, 25, 419-423.	1.1	17
326	Restoration of fibroblast growth factor receptor 2IIIb enhances the chemosensitivity of human prostate cancer cells. Oncology Reports, 2014, 32, 65-70.	1.2	12
327	Loss of function of SWI/SNF chromatin remodeling genes leads to genome instability of human lung cancer. Oncology Reports, 2015, 33, 283-291.	1.2	43
328	Molecular diagnosis in lung diseases. Frontiers in Bioscience - Landmark, 2015, 20, 644-688.	3.0	3
329	Scientific Rationale Supporting the Clinical Development Strategy for the Investigational Aurora A Kinase Inhibitor Alisertib in Cancer. Frontiers in Oncology, 2015, 5, 189.	1.3	47
330	New Discoveries for the Treatment of Lung Cancer and the Role of Small Biopsy Material. , 2015, , 129-154.		0
331	Distinct genetic alterations in small cell carcinoma from different anatomic sites. Experimental Hematology and Oncology, 2015, 4, 2.	2.0	30
332	Relationship between SLCO1B3 and ABCA3 polymorphisms and imatinib response in chronic myeloid leukemia patients. Hematology, 2015, 20, 137-142.	0.7	20
333	Genome-wide analysis of histone modifications by ChIP-chip to identify silenced genes in gastric cancer. Oncology Reports, 2015, 33, 2567-2574.	1.2	8
334	Small cell lung cancer: Where do we go from here?. Cancer, 2015, 121, 664-672.	2.0	459
335	The Hydrolysed Products of Iridoid Glycosides Can Enhance Imatinib Mesylate-Induced Apoptosis in Human Myeloid Leukaemia Cells. Phytotherapy Research, 2015, 29, 434-443.	2.8	11
336	Plasma circulating microRNA-944 and microRNA-3662 as potential histologic type-specific early lung cancer biomarkers. Translational Research, 2015, 166, 315-323.	2.2	54

#	ARTICLE	IF	CITATIONS
337	Study on extracellular matrix metalloproteinase inducer and human epidermal growth factor receptor-2 protein expression in papillary thyroid carcinoma using a quantum dot-based immunofluorescence technique. <i>Experimental and Therapeutic Medicine</i> , 2015, 9, 1331-1335.	0.8	5
338	Notch Pathway Inhibition Using PF-03084014, a $\hat{I}^3$ -Secretase Inhibitor (GSI), Enhances the Antitumor Effect of Docetaxel in Prostate Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 4619-4629.	3.2	73
339	A combination of desmopressin and docetaxel inhibit cell proliferation and invasion mediated by urokinase-type plasminogen activator (uPA) in human prostate cancer cells. <i>Biochemical and Biophysical Research Communications</i> , 2015, 464, 848-854.	1.0	22
340	Long-term cognitive dysfunction in the rat following docetaxel treatment is ameliorated by the phosphodiesterase-4 inhibitor, rolipram. <i>Behavioural Brain Research</i> , 2015, 290, 84-89.	1.2	28
342	Small Cell Lung Cancer: Will Recent Progress Lead to Improved Outcomes?. <i>Clinical Cancer Research</i> , 2015, 21, 2244-2255.	3.2	179
343	DNA methylation in small cell lung cancer defines distinct disease subtypes and correlates with high expression of EZH2. <i>Oncogene</i> , 2015, 34, 5869-5878.	2.6	195
344	GLIPR1- $\hat{I}^T$ synergizes with docetaxel in cell death and suppresses resistance to docetaxel in prostate cancer cells. <i>Molecular Cancer</i> , 2015, 14, 122.	7.9	24
345	The prognostic role of HER2 expression in ductal breast carcinoma in situ (DCIS); a population-based cohort study. <i>BMC Cancer</i> , 2015, 15, 468.	1.1	44
346	Neoadjuvant therapy for localized prostate cancer: Examining mechanism of action and efficacy within the tumor. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 182-192.	0.8	26
347	Geridonin and paclitaxel act synergistically to inhibit the proliferation of gastric cancer cells through ROS-mediated regulation of the PTEN/PI3K/Akt pathway. <i>Oncotarget</i> , 2016, 7, 72990-73002.	0.8	57
348	The Application of Cytidyl Guanosyl Oligodeoxynucleotide Can Affect the Antitumor Immune Response Induced by a Combined Protocol of Cryoablation and Dendritic Cells in Lewis Lung Cancer Model. <i>Medical Science Monitor</i> , 2016, 22, 1309-1317.	0.5	15
349	Unraveling the genomic complexity of small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2016, 5, 363-366.	1.3	27
350	A Novel Four-Way Complex Variant Translocation Involving Chromosome 46,XY,t(4;9;19;22)(q25;q34;p13.3;q11.2) in a Chronic Myeloid Leukemia Patient. <i>Frontiers in Oncology</i> , 2016, 6, 124.	1.3	5
351	KH-type splicing regulatory protein (KHSRP) contributes to tumorigenesis by promoting miR-26a maturation in small cell lung cancer. <i>Molecular and Cellular Biochemistry</i> , 2016, 422, 61-74.	1.4	27
352	Molecular profiling of neuroendocrine malignancies to identify prognostic and therapeutic markers: a Fox Chase Cancer Center Pilot Study. <i>British Journal of Cancer</i> , 2016, 115, 564-570.	2.9	88
353	Barasertib (AZD1152), a Small Molecule Aurora B Inhibitor, Inhibits the Growth of SCLC Cell Lines <i>In Vitro</i> and <i>In Vivo</i> . <i>Molecular Cancer Therapeutics</i> , 2016, 15, 2314-2322.	1.9	81
354	SCLC—State of the Art and What Does the Future Have in Store?. <i>Clinical Lung Cancer</i> , 2016, 17, 325-333.	1.1	48
355	Fisetin Enhances Chemotherapeutic Effect of Cabazitaxel against Human Prostate Cancer Cells. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 2863-2874.	1.9	37

#	ARTICLE	IF	CITATIONS
356	HER2 Gene Amplification by Fluorescence In Situ Hybridization (FISH) Compared With Immunohistochemistry (IHC) in 122 Equivocal Gastric Cancer Cases. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2016, 24, 459-464.	0.6	12
357	Anti-angiogenesis in Personalized Therapy of Lung Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2016, 893, 91-126.	0.8	17
358	Canine lymphoma: a review. <i>Veterinary Quarterly</i> , 2016, 36, 76-104.	3.0	123
359	Preclinical Assessment of the Efficacy of Anti-Angiogenic Therapies in Hepatocellular Carcinoma. <i>Ultrasound in Medicine and Biology</i> , 2016, 42, 438-446.	0.7	6
360	Lung Cancer Genomics in the Era of Accelerated Targeted Drug Development. <i>Advances in Experimental Medicine and Biology</i> , 2016, 890, 1-23.	0.8	7
361	Addition of Docetaxel to Androgen Deprivation Therapy for Patients with Hormone-sensitive Metastatic Prostate Cancer: A Systematic Review and Meta-analysis. <i>European Urology</i> , 2016, 69, 563-573.	0.9	101
362	Association of Li-Fraumeni Syndrome With Small Cell Carcinoma of the Ovary, Hypercalcemic Type and Concurrent Pleomorphic Liposarcoma of the Cervix. <i>International Journal of Gynecological Pathology</i> , 2017, 36, 593-599.	0.9	15
363	Identification of Small and Non-Small Cell Lung Cancer Markers in Peripheral Blood Using Cytokinesis-Blocked Micronucleus and Spectral Karyotyping Assays. <i>Cytogenetic and Genome Research</i> , 2017, 152, 122-131.	0.6	28
364	Unilateral Gynaecomastia in a Young Man with Chronic Myeloid Leukemia. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2017, 33, 448-450.	0.3	1
365	The effects of 1,4-dimethylpyridine in metastatic prostate cancer in mice. <i>BMC Cancer</i> , 2017, 17, 177.	1.1	3
366	Docetaxel-Related Toxic Optic Neuropathy in Management of Prostate Adenocarcinoma. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e115-e118.	0.9	6
367	Genomic Amplification of <i>CD274</i> (PD-L1) in Small-Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 1220-1226.	3.2	92
368	PD-L1 Expression by Two Complementary Diagnostic Assays and mRNA In Situ Hybridization in Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, 110-120.	0.5	108
369	In vivo evaluation of cetuximab-conjugated poly( $\gamma$ -glutamic acid)-docetaxel nanomedicines in EGFR-overexpressing gastric cancer xenografts. <i>International Journal of Nanomedicine</i> , 2017, Volume 12, 7165-7182.	3.3	20
370	Clinical Epigenetics of Lung Cancer. , 2017, , 97-133.		3
371	When and how to treat women with HER2-positive, small (pT1a-b), node-negative breast cancer?. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 128, 130-138.	2.0	6
372	Baker's™ Yeast Sensitizes Metastatic Breast Cancer Cells to Paclitaxel In Vitro. <i>Integrative Cancer Therapies</i> , 2018, 17, 542-550.	0.8	6
373	The Expanding World of N-MYC-Driven Tumors. <i>Cancer Discovery</i> , 2018, 8, 150-163.	7.7	170

#	ARTICLE	IF	CITATIONS
374	Immunohistochemistry, carcinomas of unknown primary, and incidence rates. <i>Seminars in Diagnostic Pathology</i> , 2018, 35, 143-152.	1.0	31
375	The Genomics of Prostate Cancer: emerging understanding with technologic advances. <i>Modern Pathology</i> , 2018, 31, 1-11.	2.9	47
376	Targeting CREB Pathway Suppresses Small Cell Lung Cancer. <i>Molecular Cancer Research</i> , 2018, 16, 825-832.	1.5	34
377	Genetic Susceptibility to Lung Cancer. , 2018, , 46-51.e2.		5
378	P16 is a useful supplemental diagnostic marker of pulmonary small cell carcinoma in small biopsies and cytology specimens. <i>Annals of Diagnostic Pathology</i> , 2018, 33, 23-29.	0.6	14
379	The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target. <i>Oncotarget</i> , 2018, 9, 28989-29006.	0.8	169
380	Hyper-phosphorylation of Rb S249 together with CDK5R2/p39 overexpression are associated with impaired cell adhesion and epithelial-to-mesenchymal transition: Implications as a potential lung cancer grading and staging biomarker. <i>PLoS ONE</i> , 2018, 13, e0207483.	1.1	8
381	Androgen-responsive tripartite motif 36 enhances tumor-suppressive effect by regulating apoptosis-related pathway in prostate cancer. <i>Cancer Science</i> , 2018, 109, 3840-3852.	1.7	20
382	Analysis of outpatient HER2 testing in New York state using the statewide planning and research cooperative system. <i>Pharmacogenomics</i> , 2018, 19, 1395-1401.	0.6	2
383	Issues and promises of bevacizumab in prostate cancer treatment. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 707-717.	1.4	22
384	Durable complete responses in some recurrent high-grade glioma patients treated with Toca 511 + Toca FC. <i>Neuro-Oncology</i> , 2018, 20, 1383-1392.	0.6	135
385	Cutaneous Angiosarcoma: The Possibility of New Treatment Options Especially for Patients with Large Primary Tumor. <i>Frontiers in Oncology</i> , 2018, 8, 46.	1.3	68
386	Whole-Exome Sequencing of Sinonasal Small Cell Carcinoma Arising within a Papillary Schneiderian Carcinoma In Situ. <i>Otolaryngology - Head and Neck Surgery</i> , 2018, 159, 859-865.	1.1	5
387	Her2 Ile655Val polymorphism and its association with breast cancer risk: an updated meta-analysis of case-control studies. <i>Scientific Reports</i> , 2018, 8, 7427.	1.6	16
388	Molecular Basis of Pulmonary Disease. , 2018, , 347-386.		0
390	The impact of smoking and the influence of other factors on lung cancer. <i>Expert Review of Respiratory Medicine</i> , 2019, 13, 761-769.	1.0	35
391	Molecular heterogeneity in lung cancer: from mechanisms of origin to clinical implications. <i>International Journal of Medical Sciences</i> , 2019, 16, 981-989.	1.1	104
392	Prognostic impact of tumor mutation burden and the mutation in KIAA1211 in small cell lung cancer. <i>Respiratory Research</i> , 2019, 20, 248.	1.4	12

#	ARTICLE	IF	CITATIONS
393	Androgen receptor splicing variant 7: Beyond being a constitutively active variant. <i>Life Sciences</i> , 2019, 234, 116768.	2.0	17
394	Emerging therapeutic agents for genitourinary cancers. <i>Journal of Hematology and Oncology</i> , 2019, 12, 89.	6.9	33
395	Assessment of the Molecular Mechanism of Action of SB3, a Trastuzumab Biosimilar. <i>BioDrugs</i> , 2019, 33, 661-671.	2.2	11
396	&lt;p&gt;Synergistic effect of a retinoid X receptor-selective ligand bexarotene and docetaxel in prostate cancer&lt;/p&gt;. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 7877-7886.	1.0	5
398	Pretreatment with Gemcitabine/5-Fluorouracil Enhances the Cytotoxicity of Trastuzumab to HER2-Negative Human Gallbladder Cancer Cells In Vitro and In Vivo. <i>BioMed Research International</i> , 2019, 2019, 1-12.	0.9	7
399	Randomized-controlled phase II trial of salvage chemotherapy after immunization with a TP53-transfected dendritic cell-based vaccine (Ad.p53-DC) in patients with recurrent small cell lung cancer. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 517-527.	2.0	39
400	The Genomics of Prostate Cancer: A Historic Perspective. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2019, 9, a034942.	2.9	11
401	Cancer of the Lung. , 2020, , 1108-1158.e16.		11
402	Hereditary predispositions to tumors, tumor suppressor genes, and their clinico-genomic complexities. , 2020, , 105-144.		0
403	Chemotherapy impacts on the cellular response to CDK4/6 inhibition: distinct mechanisms of interaction and efficacy in models of pancreatic cancer. <i>Oncogene</i> , 2020, 39, 1831-1845.	2.6	25
404	Effect of genetic variation in Notch regulator DTX1 on SCLC prognosis compared with the effect on NSCLC prongosis. <i>Thoracic Cancer</i> , 2020, 11, 2698-2703.	0.8	2
405	&lt;p&gt;Novel Therapeutic Strategies for CDK4/6 Inhibitors in Metastatic Castrate-Resistant Prostate Cancer&lt;/p&gt;. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 10499-10513.	1.0	16
406	Immunotherapy as a treatment for small cell lung cancer: a case report and brief review. <i>Translational Lung Cancer Research</i> , 2020, 9, 393-400.	1.3	3
407	The novel lncRNA PTTG3P is downregulated and predicts poor prognosis in non-small cell lung cancer. <i>Archives of Medical Science</i> , 2020, 16, 931-940.	0.4	9
408	Single-Cell Transcriptomics Analysis Identifies Nuclear Protein 1 as a Regulator of Docetaxel Resistance in Prostate Cancer Cells. <i>Molecular Cancer Research</i> , 2020, 18, 1290-1301.	1.5	25
409	MEN1 deficiency leads to neuroendocrine differentiation of lung cancer and disrupts the DNA damage response. <i>Nature Communications</i> , 2020, 11, 1009.	5.8	24
410	&lt;p&gt;Chinese Expert Consensus on the Diagnosis and Treatment of Castration-Resistant Prostate Cancer (2019 Update)&lt;/p&gt;. <i>Cancer Management and Research</i> , 2020, Volume 12, 2127-2140.	0.9	12
411	Treatment and resistance mechanisms in castration-resistant prostate cancer: new implications for clinical decision making?. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 149-163.	1.1	4